160 related articles for article (PubMed ID: 25387875)
1. Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy.
Barayan GA; Aprikian AG; Hanley J; Kassouf W; Brimo F; Bégin LR; Tanguay S
World J Urol; 2015 Sep; 33(9):1275-80. PubMed ID: 25387875
[TBL] [Abstract][Full Text] [Related]
2. Morbidity of focal therapy in the treatment of localized prostate cancer.
Barret E; Ahallal Y; Sanchez-Salas R; Galiano M; Cosset JM; Validire P; Macek P; Durand M; Prapotnich D; Rozet F; Cathelineau X
Eur Urol; 2013 Apr; 63(4):618-22. PubMed ID: 23265382
[TBL] [Abstract][Full Text] [Related]
3. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
4. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.
Bahn D; de Castro Abreu AL; Gill IS; Hung AJ; Silverman P; Gross ME; Lieskovsky G; Ukimura O
Eur Urol; 2012 Jul; 62(1):55-63. PubMed ID: 22445223
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
6. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
7. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
[TBL] [Abstract][Full Text] [Related]
8. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
9. A prospective clinical trial of HIFU hemiablation for clinically localized prostate cancer.
van Velthoven R; Aoun F; Marcelis Q; Albisinni S; Zanaty M; Lemort M; Peltier A; Limani K
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):79-83. PubMed ID: 26597660
[TBL] [Abstract][Full Text] [Related]
10. Histologic upgrading in patients eligible for active surveillance on saturation biopsy.
Chung PH; Darwish OM; Roehrborn CG; Kapur P; Lotan Y
Can J Urol; 2015 Feb; 22(1):7656-60. PubMed ID: 25694015
[TBL] [Abstract][Full Text] [Related]
11. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
12. Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
Galego P; Silva FC; Pinheiro LC
Int Braz J Urol; 2015; 41(2):353-9. PubMed ID: 26005979
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
[TBL] [Abstract][Full Text] [Related]
14. Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.
Preston MA; Feldman AS; Coen JJ; McDougal WS; Smith MR; Paly JJ; Carrasquillo R; Wu CL; Dahl DM; Barrisford GW; Blute ML; Zietman AI
Urol Oncol; 2015 Sep; 33(9):383.e9-16. PubMed ID: 26059076
[TBL] [Abstract][Full Text] [Related]
15. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy.
Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S
Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671
[TBL] [Abstract][Full Text] [Related]
16. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
[TBL] [Abstract][Full Text] [Related]
17. Utility of Ultrasound in the Diagnosis, Treatment, and Follow-up of Prostate Cancer: State of the Art.
Chen FK; de Castro Abreu AL; Palmer SL
J Nucl Med; 2016 Oct; 57(Suppl 3):13S-18S. PubMed ID: 27694164
[TBL] [Abstract][Full Text] [Related]
18. Focal therapy in the treatment of localised prostate cancer: primum non nocere.
Challacombe BJ; Murphy DG
Eur Urol; 2013 Apr; 63(4):623-4; discussion 625-6. PubMed ID: 23290301
[No Abstract] [Full Text] [Related]
19. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
20. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]